While the initial safety and progranulin restoration data for therapies (e.g., AL001 in INFRONT3) and the GRN gene replacement studies (e.g., PROCLAIM, ASPIRE-FTD) are encouraging, their translation to routine clinical practice faces significant hurdles. This evidence concerns the gene GRN and frontotemporal dementia.